Does docetaxel prolong survival of patients with non ‐metastatic castration‐resistant prostate cancer?

ConclusionsEarlier induction of docetaxel in nmCRPC patients may prolong OS. Further prospective studies in more patients will be required to confirm our findings.

Source: The Prostate - February 23, 2018 Category: Urology & Nephrology Authors: Kagenori Ito, Takahiro Kimura, Hajime Onuma, Ryuji Tabata, Tatsuya Shimomura, Kenta Miki, Masayuki Tomita, Shin Egawa Tags: ORIGINAL ARTICLE Source Type: research